B-cell neoplasm

Summary

B-cell neoplasm (MONDO:0004095) is a cancer (an umbrella term covering 5 Mondo subtypes) and 151 clinical trials. Top therapeutic interventions include inotuzumab ozogamicin, ibrutinib, and polatuzumab vedotin. A subtype of leukocyte disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 151

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	B-cell neoplasm
Mondo ID	MONDO:0004095
MeSH	D016393
DOID	DOID:707
NCIT	C27907
UMLS	C0079731
MedGen	86953
GARD	0005877
Is cancer (heuristic)	yes

Also known as: B-cell neoplasm · lymphoma, B-cell

Data availability: 2 cell lines.

Disease family

This is a subtype of leukocyte disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm

Related subtypes (22): human monocytic ehrlichiosis, B cell deficiency, leukopenia, dendritic cell sarcoma, human granulocytic anaplasmosis, T-cell leukemia, phagocyte bactericidal dysfunction, EBV-positive T-cell lymphoproliferative disorder of childhood, small intestinal enteropathy-associated T-cell lymphoma, pituitary gland basophil adenoma, leukostasis, mastocytosis, hereditary neutrophilia, Pelger-Huet anomaly, functional neutrophil defect, thymoma type B, POEMS syndrome, Langerhans cell histiocytosis, subcutaneous panniculitis-like T-cell lymphoma, eosinophil peroxidase deficiency, eosinophil disorder, mast cell activation syndrome

Subtypes (5): lymphoplasmacytic lymphoma, neoplasm of mature B-cells, B-cell non-Hodgkin lymphoma, high-grade B-cell lymphoma double-hit/triple-hit, large B-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

2 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Loncastuximab Tesirine	Approved (phase 4)
Polatuzumab Vedotin	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 151.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	46
PHASE1	44
Not specified	28
PHASE1/PHASE2	23
PHASE4	4
PHASE3	3
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03229200	PHASE4	ACTIVE_NOT_RECRUITING	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT06609304	PHASE4	RECRUITING	Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT02992834	PHASE4	UNKNOWN	Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
NCT04152577	PHASE4	UNKNOWN	R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
NCT07188558	PHASE3	RECRUITING	A Study to Investigate Ronde-cel Versus Investigator’s Choice CD19 CAR T-Cell Therapy
NCT00147121	PHASE2/PHASE3	COMPLETED	Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
NCT00329030	PHASE3	COMPLETED	Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin’s Lymphoma (BMTCTN0401)
NCT05431179	PHASE3	WITHDRAWN	A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT02911142	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
NCT03162536	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03620578	PHASE2	ACTIVE_NOT_RECRUITING	DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL
NCT03995147	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
NCT04594798	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
NCT04842877	PHASE2	ACTIVE_NOT_RECRUITING	Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
NCT05263583	PHASE2	ACTIVE_NOT_RECRUITING	Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT05421663	PHASE1/PHASE2	RECRUITING	A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05463263	PHASE1/PHASE2	RECRUITING	A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT06045910	PHASE1/PHASE2	RECRUITING	A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
NCT06381830	PHASE2	RECRUITING	Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin’s Lymphoma
NCT06508931	PHASE2	RECRUITING	Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
NCT06954805	PHASE2	RECRUITING	Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
NCT07502872	PHASE2	NOT_YET_RECRUITING	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
NCT00038571	PHASE2	COMPLETED	Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
NCT00051025	PHASE2	COMPLETED	Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin’s Lymphoma (NHL)
NCT00051597	PHASE1/PHASE2	COMPLETED	A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
NCT00061425	PHASE1/PHASE2	COMPLETED	Treatment of Non-Hodgkin’s Lymphoma With 90Y-hLL2 IgG
NCT00156013	PHASE1/PHASE2	COMPLETED	Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
NCT00210314	PHASE2	COMPLETED	Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma
NCT00210366	PHASE2	TERMINATED	Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma
NCT00210379	PHASE2	COMPLETED	Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin’s Lymphoma
NCT00211276	PHASE2	COMPLETED	A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin’s Lymphoma
NCT00216164	PHASE2	TERMINATED	Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00220285	PHASE2	COMPLETED	Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin’s Lymphoma
NCT00379574	PHASE1/PHASE2	COMPLETED	Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
NCT00394693	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
NCT00413959	PHASE2	TERMINATED	VELCADE,Rituximab,Cyclophosphamide and Decadron
NCT00455897	PHASE2	TERMINATED	CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin’s Lymphoma
NCT00482053	PHASE2	TERMINATED	Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
NCT00498043	PHASE2	COMPLETED	A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
NCT00498914	PHASE2	TERMINATED	Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
INOTUZUMAB OZOGAMICIN	4	5
IBRUTINIB	4	4
POLATUZUMAB VEDOTIN	4	4
TAFASITAMAB	4	3
AXICABTAGENE CILOLEUCEL	4	2
BRENTUXIMAB VEDOTIN	4	2
GLOFITAMAB	4	2
OBINUTUZUMAB	4	2
CARMUSTINE	4	1
CLOFARABINE	4	1
CYANOCOBALAMIN	4	1
DENILEUKIN DIFTITOX	4	1
DEXAMETHASONE SODIUM PHOSPHATE	4	1
DIPHENHYDRAMINE	4	1
FLUDEOXYGLUCOSE F 18	4	1
IDARUBICIN	4	1
LENOGRASTIM	4	1
MARAVIROC	4	1
PIRTOBRUTINIB	4	1
PRALATREXATE	4	1
RETIFANLIMAB	4	1
RITUXIMAB	4	1
ROFLUMILAST	4	1
TAGRAXOFUSP	4	1
TOSITUMOMAB	4	1
IBERDOMIDE	3	6
LISOCABTAGENE MARALEUCEL	3	3
CIRMTUZUMAB	3	1
EPRATUZUMAB	3	1
FAVEZELIMAB	3	1